Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

HORSHOLM, Denmark, July 14 /PRNewswire/ -- The Board of Directors of Santaris Pharma has approved the Interim Report for the period 1 January to 30 June 2009.

    - The loss after tax realised in the 2nd quarter of 2009 was
      21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd
      quarter of 2008.

    - As at June 30, 2009 the capital resources totalled 175,4m
      DKK (23,6m EUR).

    - In Q2 the SPC3649 compound targeting hepatitis C finalized a
      single dose First/In/Man study with encouraging results and a multiple
      ascending dose study in healthy volunteers is scheduled to commence in
      Q3 2009.

    - Santaris Pharma's new lead candidate SPC4955 targeting
      apoliproteinB, the major cholesterol carrying protein in the blood, has
      been selected for preclinical trials.

    - Lead candidates targeting PCSK9, which is known to play a
      critical role in regulating cholesterol levels, have been selected for
      pharmacological studies.

    - The Collaboration with the Company's 3rd partner, Wyeth, was
      initiated during the first months of 2009 and is progressing according
      to the plan.


    (Logo:http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

During the first half of 2009 Santaris Pharma continued to make satisfactory progress in its research and development programs within miRNA, metabolic disorders and infectious diseases. Key milestones achieved and other events during the quarter are summarized below.

Development

SPC3649-HCV

SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and t
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... JH Technologies announces the ... Irvine. JH Technologies, a leader in sales and ... an expanded partnership with Leica Microsystems into the Southern ... analysis solutions will be featured at the grand opening ... showroom facility is located within the JH Technologies office’s ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 ... maker of MD-Cu 29 antimicrobial copper, announces Gilmour ... points to the first EPA-registered antimicrobial solid touch surface ... copper is a reasonably priced surface that kills greater ... 2 hours of exposure. 1 ...
(Date:9/17/2014)... , 17 de septiembre de 2014 /PRNewswire/ ... principal proveedor mundial de soluciones logísticas avanzadas ... de la vida, anunció hoy la contratación ... global con sede en Rótterdam, Países Bajos, ... clientes Europa en rápido crecimiento. Según los ...
(Date:9/17/2014)... The Pistoia Alliance, a global not ... to innovation in life sciences R&D through pre-competitive ... as Executive Director Business Development North America, as ... , Carmen joins the Pistoia Alliance from Accelrys ... Accelrys, she managed various life sciences and material ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Acid Isolation , Kit , , ... , of histologists and pathologists ... and making patient diagnoses. More than 400 million FFPE , ... these samples can be tied to clinical data. Using one simple ...
... Prevalence and Roles of ... than 200 miRNAs have been cloned , ... apparently regulates multiple genes, and miRNAs are thought to , ... predict mRNA target sites for miRNAs [2,3]. A ...
... , RNA later ... sample collection and during shipping. , Whether ... you can use this aqueous, non-toxic Tissue Collection:RNA , ... -20C. , ...
Cached Biology Technology:Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 2Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 3Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 2Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 3Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 5Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 6Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 7Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 8Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 9Preserve Samples for RNA Expression Microarrays RNAlater Around the World 2Preserve Samples for RNA Expression Microarrays RNAlater Around the World 3Preserve Samples for RNA Expression Microarrays RNAlater Around the World 4Preserve Samples for RNA Expression Microarrays RNAlater Around the World 5
(Date:9/16/2014)... (September 17, 2014)The North American Menopause Society (NAMS) ... comprehensive care of midlife womenon everything from hot ... North American Menopause Society Recommendations for Clinical Care ... the Society,s journal Menopause . This is ... the care of midlife women freely available to ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... 10-km diameter chunk of rock hit the Yukatan peninsula near ... force of 100 teratons of TNT. It left a crater ... global earthquakes and volcanism are widely accepted to have wiped ... the mammals. But what happened to the plants on which ... from the University of Arizona reveals that the meteorite impact ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... born to obese mothers are at risk for iron ... a study to be presented Saturday, April 30, at ... In nonpregnant adults, obesity-related inflammation hinders the transport ... iron deficiency anemia. When a woman is pregnant, iron ...
... an August 2010 ban on federal funding of embryonic stem ... stem cells function and how they can be harnessed to ... ruling has been welcomed by the Obama Administration, which attempted ... top researchers in the field, including Arnold Kriegstein, MD, PhD, ...
... a groundbreaking new videojournal to complement the ... & Advanced Surgical Techniques has been ... ( http://www.liebertpub.com ). Videoscopy ( http://www.liebertpub.com/products/product.aspx?pid=390 ) ... of the latest techniques and technologies used ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... identified as the cellular homolog of the avian ... D have been shown to be almost identical ... involved in dimerization and DNA binding, whereas their ... diverge. Antigen: The antibody ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
... Buffer, used in conjunction with eBioscience ... be used to fix and permeabilize ... of cytokines and other cytoplasmic and/or ... specially formulated for reducing non-specific staining ...
Biology Products: